Using a self-turning-off gene editing tool at different ages helps improve Huntington's disease symptoms over time in mice

Self-inactivating AAV-CRISPR reduced mutant huntingtin and improved Huntington's-like deficits in BAC226Q mice.

This was a preclinical gene-editing study in BAC226Q mouse brains, where conventional and self-inactivating SaCas9 systems lowered mHTT protein by 60 to 90%, reduced aggregation by 90%, and improved pathology, motor signs, weight, and lifespan across treatment ages.

This is proof-of-concept mouse data, so human delivery, safety, and clinical efficacy were not tested.